The ICB-naïve patient had a PD-L1-low tumor and had received prior HPV16 E7 T cell receptor (TCR) gene engineered T-cell therapy following standard-of-care treatment with chemotherapy and bevacizumab for cervical cancer. The gene discussed is CD274; the disease is cervical carcinoma.